Oritavancin Injection — Competitive Intelligence Brief

Oritavancin Injection (Oritavancin Injection) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lipoglycopeptide antibiotic. Area: Infectious Disease.

marketed Lipoglycopeptide antibiotic Bacterial peptidoglycan precursors (D-Ala-D-Ala) and lipid II Infectious Disease Small molecule

Target snapshot

Oritavancin Injection (Oritavancin Injection) — University of Pennsylvania. Oritavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to peptidoglycan precursors and disrupting cross-linking.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oritavancin Injection TARGET	Oritavancin Injection	University of Pennsylvania	marketed	Lipoglycopeptide antibiotic	Bacterial peptidoglycan precursors (D-Ala-D-Ala) and lipid II
Dalbavancin via Intravenous Administration	Dalbavancin via Intravenous Administration	University of Colorado, Denver	marketed	Lipoglycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursors
Dalbavancin via Intraperitoneal Administration	Dalbavancin via Intraperitoneal Administration	University of Colorado, Denver	marketed	Lipoglycopeptide antibiotic	Bacterial peptidoglycan (D-Ala-D-Ala)
Dalbavancin administration	Dalbavancin administration	Assistance Publique - Hôpitaux de Paris	phase 3	Lipoglycopeptide antibiotic	Bacterial peptidoglycan (D-Ala-D-Ala)
Single-Dose IV Oritavancin Diphosphate	Single-Dose IV Oritavancin Diphosphate	Melinta Therapeutics, Inc.	phase 3	Lipoglycopeptide antibiotic	Lipid II
IV Dalbavancin	IV Dalbavancin	Durata Therapeutics Inc., an affiliate of Allergan plc	phase 3	Lipoglycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lipoglycopeptide antibiotic class)

1. University of Colorado, Denver · 2 drugs in this class
2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
3. Durata Therapeutics Inc., an affiliate of Allergan plc · 1 drug in this class
4. Melinta Therapeutics, Inc. · 1 drug in this class
5. University of Pennsylvania · 1 drug in this class